title: Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
authors: D
authors: D
authors: Dumitrescu
authors: C
authors: C
authors: Seck
authors: Henrik
authors: H
authors: ten Freyhaus
authors: F
authors: F
authors: Gerhardt
authors: E
authors: E
authors: Erdmann
authors: S
authors: S
authors: Rosenkranz
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001794:Blood Pressure; D000069439:Dasatinib; D065627:Familial Primary Pulmonary Hypertension; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000628:therapy*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015272:Pulmonary Medicine / Q000379:methods; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D018497:Ventricular Dysfunction, Right / Q000150:complications
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib